Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) saw a significant decrease in short interest in September. As of September 15th, there was short interest totalling 444,251 shares, a decrease of 37.6% from the August 31st total of 712,505 shares. Based on an average daily volume of 794,436 shares, the short-interest ratio is presently 0.6 days. Approximately 3.0% of the shares of the stock are sold short.

Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) opened at 2.64 on Tuesday. The company’s 50-day moving average price is $1.80 and its 200-day moving average price is $1.80. Catabasis Pharmaceuticals has a 52-week low of $1.08 and a 52-week high of $6.07. The stock’s market cap is $59.35 million.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. Analysts expect that Catabasis Pharmaceuticals will post ($1.39) earnings per share for the current year.

CATB has been the topic of several research reports. Citigroup Inc. reiterated a “hold” rating and issued a $1.50 price target on shares of Catabasis Pharmaceuticals in a research report on Friday. Oppenheimer Holdings, Inc. cut their price objective on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research report on Tuesday, August 15th. HC Wainwright lifted their price objective on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Wedbush restated an “outperform” rating and set a $4.00 price objective on shares of Catabasis Pharmaceuticals in a research report on Wednesday, June 21st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Catabasis Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $4.00.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in shares of Catabasis Pharmaceuticals during the first quarter worth $106,000. Oppenheimer & Co. Inc. acquired a new position in shares of Catabasis Pharmaceuticals in the 1st quarter valued at $144,000. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Catabasis Pharmaceuticals in the 2nd quarter valued at $271,000. Institutional investors and hedge funds own 32.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/short-interest-in-catabasis-pharmaceuticals-inc-catb-drops-by-37-6/1604130.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.